Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale

An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.

Alterity Therapeutics has unveiled new analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy, showing the drug reduced functional decline versus placebo over 52 weeks on MuSyCA, a newly developed composite scale that captures both daily function and neurological exam measures. The data, presented at the American Academy of Neurology meeting, reinforce prior evidence of efficacy from UMSARS-based assessments and support ATH434’s profile as a potential first disease-modifying therapy for MSA, strengthening the company’s position as it prepares for Phase 3 discussions with regulators.

MuSyCA, created by an NIH-funded international consortium to sharpen detection of MSA progression in trials, demonstrated robust sensitivity to disease worsening in placebo patients and highlighted clinically meaningful slowing of decline in ATH434-treated groups. The integration of patient-reported function with clinical assessment, and the planned incorporation of biomarkers such as neurofilament light chain and imaging, could improve future trial design for MSA and enhance Alterity’s ability to demonstrate long-term benefit to patients and regulators in a field with no approved disease-modifying treatments.

The most recent analyst rating on (AU:ATH) stock is a Buy with a A$0.01 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the AU:ATH Stock Forecast page.

More about Alterity Therapeutics

Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative disorders, particularly Parkinsonian conditions such as Multiple System Atrophy. Its lead oral candidate ATH434 is designed to reduce abnormal brain iron accumulation and protein aggregation, and has received Fast Track and Orphan Drug designations for MSA in the U.S. and Europe.

Average Trading Volume: 5,614,265

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$97.88M

See more data about ATH stock on TipRanks’ Stock Analysis page.